



FGFR2 Positive Control

Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

FGFR2 Positive Control

(Human, recombinant protein expressed in Sf9)
Cat# CY-E1082

Lot No.
For 100 Assays
(1 unit / μL x 100 μL)

Product Description:

Catalytic domain of human FGFR2 (K-sam), corresponding to 448-798 a.a. containing a N-terminal GST tag and a C-terminal His tag, expressed in recombinant Baculovirus-infected sf9 cells. Purified by sequentially using GSH agarose and Ni-NTA agarose chromatography. The FGFR2 Positive control is designed to use for CycLex FGFR2 Kinase Assay/Inhibitor Screening Kit (Cat# CY-1082). The FGFR2 Positive Control should be added to the well at 1 unit/well. For instance, diluted positive control 1:10, use 10 μL for 1 assay. Unused FGFR2 Positive Control should be stored at -70°C .

Product Size: Recombinant FGFR2: 100 units/100 μL

Formulation: The FGFR2 Positive Control is supplied frozen in a buffer containing 20mM Hepes-KOH (pH 7.5), 1 % BSA, 1mM EDTA, 2 mM DTT, 50mM NaCl, 0.03 % Brij35 and 50% glycerol.

Source: Human FGFR2 containing N-terminal GST-tag and C-terminal His tag, expressed in sf9 cells.

Molecular Weight: FGFR2 Positive Control demonstrates a single 65 kDa bands by SDS-PAGE analysis.

Purity: FGFR2 Positive Control is greater than 70 % pure as determined by SDS-PAGE analysis.

Substrates: FGFR2 phosphorylates poly[Glu, Tyr] 4:1 as a exogenous substrate.

Inhibitors: PD173074 and SU5402 are known as selective small molecule FGFRs inhibitor.

Unit Definition: One unit is defined as the amount of kinase required to incorporate 1 nmol of phosphate into the FGFR2 (autophosphorylation) under oligomerized/activated condition per 60 minute at 30°C .

Assay Conditions: Assay activity of FGFR2 in a 50 μL reaction containing 20 mM Hepes KOH (pH 7.5), 4 mM MgCl_2 , 2 mM MnCl_2 , 1 mM DTT, 50 μM [γ - ^{32}P] ATP (1 μCi), and 4 μg of CycLex-"Tyrosine kinase-binding module". Start the reaction by adding 10 μL of the enzyme, diluted 10-fold in a buffer containing 20 mM Hepes KOH (pH 7.5), 1 mM DTT, 0.03 % Brij35. Incubate for 60 minutes at 30°C . Terminate the reaction by adding 600 μL of cold 10 % TCA solution containing 0.2 % Sodium pyrophosphate and stand on ice for 15 min. Filtrate acid insoluble material through GFC filters (Whatman Inc.), wash 4 times with 1 % TCA and rinse filters with ethanol. Dry filters and count in a liquid scintillation counter.

Storage and Stability: Stable for 12 months at -70°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot enzyme to avoid repeated freezing and thawing.



FGFR2 Positive Control

Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

Related Products:

* CycLex FGFR2 Kinase Assay/Inhibitor Screening Kit: Cat# CY-1082

References:

1. Fibroblast growth factors David M Ornitz and Nobuyuki Itoh *Genome Biology* **2** : reviews 3005.1-3005.12, 2001
2. Johnson D, Williams L: Structural and functional diversity in the FGF receptor multigene family. *Adv Cancer Res* **60**:1-41, 1993
3. Plontnikov A, Schlessinger J, Hubbard S, Mohammadi M: Structural basis of fgf receptor dimerization and activation. *Cell* **98**:641-650, 1999
4. Luqmani Y, Graham M, Coombes R: Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. *Br J Cancer* 1992, **66**:271-280. 1992
5. Adnane J, Gaudray P, Dionne C, *et al*: BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. *Oncogene* **6**:659-663, 1991
6. Penault-Llorca F, Bertucci F, Adelaide J: Expression of FGF and FGF receptor genes in human breast cancer. *Int J Cancer* **61**:170-176, 1991
7. Preston, R. A.; Post, J. C.; Keats, B. J. B.; Aston, C. E.; Ferrell, R. E.; Priest, J.; Nouri, N.; Losken, H. W.; Morris, C. A.; Hurtt, M. R.; Mulvihill, J. J.; Ehrlich, G. D. : A gene for Crouzon craniofacial dysostosis maps to the long arm of chromosome 10. *Nature Genet.* **7**: 149-153, 1994
8. Jabs, E. W.; Li, X.; Scott, A. F.; Meyers, G.; Chen, W.; Eccles, M.; Mao, J.; Charnas, L. R.; Jackson, C. E.; Jaye, M. : Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. *Nature Genet.* **8**: 275-279, 1994
9. Reardon, W.; Winter, R. M.; Rutland, P.; Pulleyn, L. J.; Jones, B. M.; Malcolm, S. : Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. *Nature Genet.* **8**: 98-103, 1994
10. Wilkie, A. O. M.; Slaney, S. F.; Oldridge, M.; Poole, M. D.; Ashworth, G. J.; Hockley, A. D.; Hayward, R. D.; David, D. J.; Pulleyn, L. J.; Rutland, P.; Malcolm, S.; Winter, R. M.; Reardon, W. : Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. *Nature Genet.* **9**: 165-172, 1995
11. Lajeunie, E.; Ma, H. W.; Bonaventure, J.; Munnich, A.; Le Merrer, M.; Renier, D. : FGFR2 mutations in Pfeiffer syndrome. *Nature Genet.* **9**: 108, 1995

PRODUCED BY

CycLex Co., Ltd.
1063-103 Terasawaoka
Ina, Nagano 396-0002
Japan
Fax: +81-265-76-7618
e-mail: info@cyclex.co.jp
URL: <http://www.cyclex.co.jp>

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.